A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
In July 2023, the paper announced it will reduce its print schedule to three days a week: Tuesday, Thursday and Saturday. Also, the newspaper will transition from carrier to postal delivery. In September 2024, Napa Valley Publishing, which publishes the paper, was sold by Lee Enterprises to Hoffmann Media Group.
=== Purification of heterotetramers === Ion-exchange chromatography is useful for isolating specific heterotetrameric protein assemblies, allowing purification of specific complexes according to both the number and the position of charged peptide tags. Nickel affinity chromatography may also be employed for heterotetramer purification.
==== Natural resources ==== Initially, some mining executives feared that Castillo may nationalize mining, as he alluded during his electoral campaign. However, as of late, the Castillo Administration has toned down its rhetoric and showed greater willingness to work with private companies. Castillo has pledged to raise taxes on mining companies, and to make sure that projects are "socially profitable" for local mining communities. Prime Minister Guido Bellido has stated that he welcomes investment, as long as it means the development of the population. Later, the then prime minister stated that the energy sector should be under government control, while using the Camisea Gas Project as an example. In response, Economic Minister Pedro Francke ruled out expropriating the Camisea gas field. Francke also claimed that Bellido's call for government control of the energy sector was actually referring to state participation in the construction of a proposed natural gas pipeline, the Gran Gasoducto del Sur. However, PM Bellido later urged for the contract with the Camisea gas field to be renegotiated, threatening to nationalize the gas field if higher taxes aren't paid. The Prime Minister has also stated that strategic resources cannot remain in private hands. The Minister of Justice, Aníbal Torres, has stated that he's in favor of renegotiating the contract with Camisea, "like almost all the other ministers." However, Torres rejected the possibility of unilateral nationalization, and said that there were no talks about nationalization within the cabinet.
Sources: en.wikipedia.org
=== Product recalls === In May 2006, a sale of the seats from Arsenal F.C.'s old stadium, Highbury in London, England was cancelled when the seats were discovered to contain trace amounts of cadmium. Reports of high levels of cadmium use in children's jewelry in 2010 led to a US Consumer Product Safety Commission investigation. The U.S. CPSC issued specific recall notices for cadmium content in jewelry sold by Claire's and Wal-Mart stores. In June 2010, McDonald's voluntarily recalled more than 12 million promotional Shrek Forever After 3D Collectible Drinking Glasses because of the cadmium levels in paint pigments on the glassware. The glasses were manufactured by Arc International, of Millville, New Jersey, USA.
Marshall Islands site Entry at Oceandots.com at the Wayback Machine (archived December 23, 2010) Annotated bibliography for Eniwetok Atoll from the Alsos Digital Library for Nuclear Issues Information on legal judgements to the people of Enewetak Nursing a nuclear test hangover (www.watoday.com.au report on Runit Dome, August 18, 2008) Enewetak Atoll Atomic Debris Cleanup Mission Survivors "This Concrete Dome Holds a Leaking Toxic Timebomb" | Foreign Correspondent on YouTube—ABC News documentary, 41 min.
The Stille reaction is a chemical reaction widely used in organic synthesis. The reaction involves the coupling of two organic groups, one of which is carried as an organotin compound (also known as organostannanes). A variety of organic electrophiles provide the other coupling partner. The Stille reaction is one of many palladium-catalyzed coupling reactions.
Sources: en.wikipedia.org
Glutamatergic means "involving the release of, or activated by, glutamate". A glutamatergic agent (or drug) is a chemical that directly modulates the excitatory amino acid (glutamate/aspartate) system in the body or brain. Examples include:
5p partial monosomy syndrome Bloom syndrome Branchiootorenal syndrome 1 Cardiofaciocutaneous syndrome 4 Christianson syndrome Congenital disorder of glycosylation, type IIw Congenital myasthenic syndrome 2A Congenital myopathy 4A, autosomal dominant Congenital myopathy 4B, autosomal recessive Creatine transporter deficiency Cutis laxa, X-linked Ehlers-Danlos syndrome, Beasley-Cohen type Granulocytopenia with immunoglobulin abnormality Hereditary spastic paraplegia 23 and 51 Intellectual disability, autosomal recessive 5 Intellectual disability, X-linked 107, 58, and 61 Knobloch syndrome Marfan syndrome Mitochondrial DNA depletion syndrome 13 Nance-Horan syndrome Oculofaciocardiodental syndrome Otofaciocervical syndrome 1 Proximal myopathy with extrapyramidal signs Radioulnar synostosis-developmental delay-hypotonia syndrome Renpenning syndrome Seckel syndrome 9 Severe X-linked myotubular myopathy SIN3A-related intellectual disability syndrome due to a point mutation Symphalangism-brachydactyly syndrome Syndromic X-linked intellectual disability 14 Torsion dystonia 4 X-linked intellectual disability with marfanoid habitus XFE progeroid syndrome
=== Infant deficiency === Comparative studies carried out in lactating mothers indicate a mean value of vitamin D content in the breast milk of 45 IU/liter. This vitamin D content is too low to meet the vitamin D requirement of 400 IU/day recommended by several government organizations ("...as breast milk is not a meaningful source of vitamin D."). The same government organizations recommend that lactating women consume 600 IU/day, but this is insufficient to raise breast milk content to deliver recommended intake. There is evidence that breast milk content can be increased, but because the transfer of the vitamin from the lactating mother's serum to milk is inefficient, this requires that she consume a dietary supplement above the government-set safe upper limit of 4,000 IU/day. Given the shortfall, there are recommendations that breast-fed infants be fed a vitamin D dietary supplement of 400 IU/day during the first year of life. If not breastfeeding, infant formulas are designed to deliver 400 IU/day for an infant consuming a liter of formula per day – a normal volume for a full-term infant after the first month.
==== NATO involvement ==== The North Atlantic Treaty Organization (NATO) has played a role in addressing the issue of drug trafficking, particularly in Afghanistan, as part of its broader security and stabilization efforts. NATO has supported counter-narcotics initiatives by assisting the Afghan government in building its capacity to combat the illegal drug trade, which is seen as a major source of funding for insurgent groups. NATO's efforts include training and equipping Afghan security forces to enhance their ability to disrupt drug trafficking networks, as well as supporting intelligence-sharing and coordination with international partners. These activities are framed within NATO's mission to promote stability and security, recognizing the link between the drug trade and threats to regional and global security. However, perspectives on NATO's involvement in counter-narcotics operations have varied, with some reports highlighting tensions with other international actors, such as the United Nations. While NATO emphasizes its contributions to reducing the drug trade through capacity-building and support for Afghan-led initiatives, other sources have noted discrepancies in reported outcomes, suggesting that the drug trade in Afghanistan remained robust despite these efforts. For instance, data from 2012 indicates that opium production continued to thrive, raising questions about the effectiveness of NATO's strategies in this domain.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.